TIPS review
Therapeutic potential of ACAT inhibitors as lipid lowering and anti-atherosclerotic agents

https://doi.org/10.1016/0165-6147(91)90546-5Get rights and content

Abstract

Hypercholesterolemia is one of the few independent risk factors definitively linked to increased morbidity and mortality due to myocardial infarction. One possible therapy of current interest is the prevention of the absorption of dietary cholesterol by inhibiting the enzyme, acyl-CoA:cholesterol acyltransferase (ACAT), which catalyses the intracellular formation of cholesterol esters. Evidence is now accumulating that suggests that ACAT inhibition may not only lower plasma cholesterol levels, but may also have a direct effect at the artery wall, where ACAT has been shown to be responsible for the accumulation of cholesterol esters in arterial lesions. Drago Sliskovic and Andrew White discuss the importance of ACAT in the lipid transport system and the consequences of its inhibition in a variety of tissues, with emphasis on both lipid-lowering and anti-atherosclerotic effects.

References (43)

  • E.F. Stange et al.
  • E.E. Largis et al.

    J. Lipid Res.

    (1989)
  • K.E. Suckling et al.

    J. Lipid Res.

    (1985)
  • L.L. Gallo et al.

    J. Lipid Res.

    (1987)
  • J.G. Heider et al.

    J. Lipid Res.

    (1983)
  • J.L. Goldstein et al.

    J. Lipid Res.

    (1984)
  • K.M. Cianflone et al.

    J. Lipid Res.

    (1990)
  • B. Middleton

    Biochem. Biophys. Res. Commun.

    (1987)
  • J.L. Smith et al.

    Clin. Chim. Acta

    (1986)
  • K. Toki et al.

    J. Atheroscler. Res.

    (1967)
  • K. Natori et al.

    Jpn. J. Pharmacol.

    (1986)
  • J.D. Albright et al.

    J. Pharm. Sci.

    (1979)
  • F. Heffron et al.

    Biochem. Pharmacol.

    (1990)
  • B. Middleton et al.

    Atherosclerosis

    (1984)
  • S.M. Grundy

    New Engl. J. Med.

    (1988)
  • J.G. Heider
  • G. Vahouny et al.

    Am. J. Physiol.

    (1957)
  • R. Haugen et al.

    Scand. J. Gastroenterol.

    (1976)
  • B. Khan et al.

    FASEB J.

    (1988)
  • T.P. Carr et al.

    Arteriosclerosis

    (1990)
  • L.M. Havekes et al.

    Biochem. J.

    (1987)
  • Cited by (241)

    • Hypolipidemic effect of dihydroisoquinoline oxaziridine in high-fat diet-fed rats

      2016, Biomedicine and Pharmacotherapy
      Citation Excerpt :

      Hyperlipidemia is a major risk factor that can facilitate the development of coronary artery disease and the progression of atherosclerotic lesions [30]. An increase in lipid profiles as a contributing factor to the pathogenesis of atherosclerosis and associated cardiac disorders has warranted increased focus on the development of novel and more effective anti hyperlipidemic agents [31,32]. Actually, the consumption of high-fat diets (HFDs) is a central risk factor for metabolic disorders linked to obesity [33].

    • Some molecular targets for antihyperlipidemic drug research

      2014, European Journal of Medicinal Chemistry
      Citation Excerpt :

      In most cell types, CE are present only in low levels, mainly as cytoplasmic lipid droplets. In plasma, CE are part of the neutral lipid cargo present in the intestinal chylomicrons and in the hepatic VLDL [67]. In the atherosclerotic disorder, chronic accumulation of CE in macrophages causes these cells to appear foamy.

    View all citing articles on Scopus
    View full text